Personalized microbiome-based approaches to metabolic syndrome management and prevention

被引:37
作者
Shapiro, Hagit [1 ]
Suez, Jotham [1 ]
Elinav, Eran [1 ]
机构
[1] Weizmann Inst Sci, Dept Immunol, 234 Herzl St, IL-76100 Rehovot, Israel
关键词
metabolic syndrome; microbiome; personalized medicine; CHAIN FATTY-ACIDS; GUT MICROBIOTA; INTESTINAL MICROBIOTA; WIDE ASSOCIATION; GLYCEMIC INDEX; DIETARY FIBER; WEIGHT-LOSS; RECEPTOR; GLUCOSE; HEALTH;
D O I
10.1111/1753-0407.12501
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Personalized or precision medicine is a novel clinical approach targeted to the individual patient and based on integration of clinical, genetic, and environmental factors that define a patient uniquely from other individuals featuring similar clinical symptoms. Such a personalized medicine approach is increasingly applied for diagnosis, clinical stratification, and treatment of metabolic syndrome (MetS)-associated risks and diseases, including obesity, type 2 diabetes, non-alcoholic fatty liver disease, and their complications. One emerging factor that governs MetS manifestations is the microbiome, the composition, function, growth dynamics, associated metabolite profile and diverse effects of which on host immune and metabolic systems can all significantly affect metabolic homeo-stasis. Interindividual differences in microbiome composition and function, as well as personal variations in microbial-derived products, pave the way towards microbiome-based personalized medicine in treating MetS-related diseases.
引用
收藏
页码:226 / 236
页数:11
相关论文
共 98 条
  • [1] Splenda alters gut microflora and increases intestinal P-glycoprotein and cytochrome P-450 in male rats
    Abou-Donia, Mohamed B.
    El-Masry, Eman M.
    Abdel-Rahman, Ali A.
    McLendon, Roger E.
    Schiffman, Susan S.
    [J]. JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES, 2008, 71 (21): : 1415 - 1429
  • [2] Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
  • [3] 2-S
  • [4] Probiotics lower plasma glucose in the high-fat fed C57BL/6J mouse
    Andersson, U.
    Branning, C.
    Ahrne, S.
    Molin, G.
    Alenfall, J.
    Onning, G.
    Nyman, M.
    Holm, C.
    [J]. BENEFICIAL MICROBES, 2010, 1 (02) : 189 - 196
  • [6] The gut microbiota as an environmental factor that regulates fat storage
    Bäckhed, F
    Ding, H
    Wang, T
    Hooper, LV
    Koh, GY
    Nagy, A
    Semenkovich, CF
    Gordon, JI
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (44) : 15718 - 15723
  • [7] The Severity of Nonalcoholic Fatty Liver Disease Is Associated With Gut Dysbiosis and Shift in the Metabolic Function of the Gut Microbiota
    Boursier, Jerome
    Mueller, Olaf
    Barret, Matthieu
    Machado, Mariana
    Fizanne, Lionel
    Araujo-Perez, Felix
    Guy, Cynthia D.
    Seed, Patrick C.
    Rawls, John F.
    David, Lawrence A.
    Hunault, Gilles
    Oberti, Frederic
    Cales, Paul
    Diehl, Anna Mae
    [J]. HEPATOLOGY, 2016, 63 (03) : 764 - 775
  • [8] Immune Regulation of Metabolic Homeostasis in Health and Disease
    Brestoff, Jonathan R.
    Artis, David
    [J]. CELL, 2015, 161 (01) : 146 - 160
  • [9] Crosstalk between Gut Microbiota and Dietary Lipids Aggravates WAT Inflammation through TLR Signaling
    Caesar, Robert
    Tremaroli, Valentina
    Kovatcheva-Datchary, Petia
    Cani, Patrice D.
    Backhed, Fredrik
    [J]. CELL METABOLISM, 2015, 22 (04) : 658 - 668
  • [10] Gut-derived lipopolysaccharide augments adipose macrophage accumulation but is not essential for impaired glucose or insulin tolerance in mice
    Caesar, Robert
    Reigstad, Christopher S.
    Backhed, Helene Kling
    Reinhardt, Christoph
    Ketonen, Maria
    Lunden, Gunnel Ostergren
    Cani, Patrice D.
    Backhed, Fredrik
    [J]. GUT, 2012, 61 (12) : 1701 - 1707